Skip to main content
Top
Published in: Clinical and Experimental Medicine 3/2018

Open Access 01-08-2018 | Original Article

Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma

Authors: Agnès Marchio, Marie Amougou Atsama, Aubin Béré, Narcisse-Patrice Komas, Dominique Noah Noah, Paul Jean Adrien Atangana, Serge-Magloire Camengo-Police, Richard Njouom, Claudine Bekondi, Pascal Pineau

Published in: Clinical and Experimental Medicine | Issue 3/2018

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is still a major killing malignancy in sub-Saharan Africa. Lifelong intoxication with aflatoxin B1 is considered as one of the primary causes of this situation. The role of aflatoxin in HCC from a given population is commonly estimated through the prevalence of R249S mutation of TP53, a hallmark for previous exposure to the mycotoxin. However, the role of AFB1 is barely known in large part of Africa. We conducted a survey on circulating cell-free DNA from 149 patients with HCC and 213 control subjects with and without liver diseases from Cameroon and Central African Republic using droplet digital PCR technique. We observed a mutation prevalence of 24.8% (n = 37/149) in patients with tumor and 5.6% (n = 12/213) in controls (P = 2.2E−07). Patients with mutations usually displayed significantly increased circulating alpha-fetoprotein (AFP) values, high hepatitis B virus (HBV) DNA loads as well as worsened values of blood cells count. Interestingly, the fraction of droplets positive for R249S was significantly larger in patients with liver cancer (15.3 ± 3.7%) than in controls (0.5 ± 0.3%, P = 7.1E−04). Our survey indicates that AFB1 is instrumental for HCC development in Middle Africa and that droplet digital PCR might be used in the region both to diagnose HCC and to conduct public health surveys on populations at risk of chronic aflatoxin intoxication.
Literature
1.
go back to reference GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. [database on the Internet]. International Agency for Research on Cancer. 2013. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. [database on the Internet]. International Agency for Research on Cancer. 2013.
2.
go back to reference Higginson J. The geographical pathology of primary liver cancer. Cancer Res. 1963;23:1624–33.PubMed Higginson J. The geographical pathology of primary liver cancer. Cancer Res. 1963;23:1624–33.PubMed
3.
go back to reference Wu F, Khlangwiset P. Health economic impacts and cost-effectiveness of aflatoxin reduction strategies in Africa: case studies in biocontrol and postharvest interventions. Food Addit Contam. 2010;27:496–509.CrossRef Wu F, Khlangwiset P. Health economic impacts and cost-effectiveness of aflatoxin reduction strategies in Africa: case studies in biocontrol and postharvest interventions. Food Addit Contam. 2010;27:496–509.CrossRef
4.
go back to reference Ott J, Stevens G, Wiersma S. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis. 2012;12:131.CrossRefPubMedPubMedCentral Ott J, Stevens G, Wiersma S. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis. 2012;12:131.CrossRefPubMedPubMedCentral
5.
go back to reference Yang J, Mohamed EA, AbdelAziz A, Shousha H, Hashem M, Nabeel M, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRefPubMed Yang J, Mohamed EA, AbdelAziz A, Shousha H, Hashem M, Nabeel M, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRefPubMed
6.
go back to reference Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429–31.CrossRefPubMed Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429–31.CrossRefPubMed
7.
go back to reference Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, et al. In human hepatocellular carcinoma, chromosome instability depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653:6–13.CrossRefPubMed Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, et al. In human hepatocellular carcinoma, chromosome instability depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653:6–13.CrossRefPubMed
8.
go back to reference Tanase A, Marchio A, Dumitrascu T, Dima S, Herlea V, Oprisan G, et al. Mutation spectrum of hepatocellular carcinoma from Eastern-European patients betrays the impact of a complex exposome. J Exp Sci Environ Epidemiol. 2014;25:256–63.CrossRef Tanase A, Marchio A, Dumitrascu T, Dima S, Herlea V, Oprisan G, et al. Mutation spectrum of hepatocellular carcinoma from Eastern-European patients betrays the impact of a complex exposome. J Exp Sci Environ Epidemiol. 2014;25:256–63.CrossRef
9.
go back to reference Marchio A, Cerapio JP, Ruiz E, Cano L, Casavilca S, Terris B, et al. Early forms of liver cancer in South America associate with low hepatitis B virus DNA burden (in revision). Marchio A, Cerapio JP, Ruiz E, Cano L, Casavilca S, Terris B, et al. Early forms of liver cancer in South America associate with low hepatitis B virus DNA burden (in revision).
10.
go back to reference Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009;286:29–37.CrossRefPubMed Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009;286:29–37.CrossRefPubMed
11.
go back to reference Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l’Homme. CR Soc Biol. 1948;142:241–3. Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l’Homme. CR Soc Biol. 1948;142:241–3.
12.
13.
go back to reference Pathak A, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52:1833–42.PubMed Pathak A, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52:1833–42.PubMed
14.
go back to reference Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawa N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.CrossRefPubMedPubMedCentral Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawa N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.CrossRefPubMedPubMedCentral
15.
go back to reference Thierry A, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.CrossRefPubMed Thierry A, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.CrossRefPubMed
16.
go back to reference Ladep N, Lesi O, Mark P, Lemoine M, Onyekwere C, Afihene M, et al. Problem of hepatocellular carcinoma in West Africa. World J Hepatol. 2014;6:783–92.CrossRefPubMedPubMedCentral Ladep N, Lesi O, Mark P, Lemoine M, Onyekwere C, Afihene M, et al. Problem of hepatocellular carcinoma in West Africa. World J Hepatol. 2014;6:783–92.CrossRefPubMedPubMedCentral
17.
go back to reference Eng J. ROC analysis: web-based calculator for ROC curves. Baltimore: Johns Hopkins University; 2014. Eng J. ROC analysis: web-based calculator for ROC curves. Baltimore: Johns Hopkins University; 2014.
18.
go back to reference Amougou Atsama M, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis. 2016;16:647.CrossRef Amougou Atsama M, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis. 2016;16:647.CrossRef
19.
go back to reference Wild C, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009;286:22–8.CrossRefPubMed Wild C, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009;286:22–8.CrossRefPubMed
20.
go back to reference Montesano R, Hainaut P, Wild C. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997;89:1844–51.CrossRefPubMed Montesano R, Hainaut P, Wild C. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997;89:1844–51.CrossRefPubMed
21.
go back to reference Hussain S, Harris C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res. 1999;428:23–32.CrossRefPubMed Hussain S, Harris C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res. 1999;428:23–32.CrossRefPubMed
22.
go back to reference Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21:493–510.CrossRefPubMed Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21:493–510.CrossRefPubMed
23.
go back to reference Kuś M, Ossowski A, Zielińska G. Comparison of three different DNA extraction methods from a highly degraded biological material. J Forens Leg Med. 2016;40:47–53.CrossRef Kuś M, Ossowski A, Zielińska G. Comparison of three different DNA extraction methods from a highly degraded biological material. J Forens Leg Med. 2016;40:47–53.CrossRef
24.
go back to reference Feldman M, Hershkovitz I, Sklan E, Kahila Bar-Gal G, Pap I, Szikossy I, et al. Detection of a tumor suppressor gene variant predisposing to colorectal cancer in an 18th century Hungarian mummy. PLoS ONE. 2016;11:e0147217.CrossRefPubMedPubMedCentral Feldman M, Hershkovitz I, Sklan E, Kahila Bar-Gal G, Pap I, Szikossy I, et al. Detection of a tumor suppressor gene variant predisposing to colorectal cancer in an 18th century Hungarian mummy. PLoS ONE. 2016;11:e0147217.CrossRefPubMedPubMedCentral
25.
go back to reference Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral
26.
go back to reference Kirk G, Camus-Randon A, Mendy M, Goedert J, Merle P, Trepo C, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst. 2000;92:148–53.CrossRefPubMed Kirk G, Camus-Randon A, Mendy M, Goedert J, Merle P, Trepo C, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst. 2000;92:148–53.CrossRefPubMed
27.
go back to reference Jackson P, Qian G, Friesen M, Zhu Y, Lu P, Wang J, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 2001;61:33–5.PubMed Jackson P, Qian G, Friesen M, Zhu Y, Lu P, Wang J, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 2001;61:33–5.PubMed
28.
go back to reference Unsal H, Yakicier C, Marçais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1994;91:822–6.CrossRefPubMed Unsal H, Yakicier C, Marçais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1994;91:822–6.CrossRefPubMed
29.
go back to reference Marchio A, Bertani S, Rojas-Rojas T, Doimi F, Terris B, Deharo E, et al. A peculiar mutation spectrum emerging from young Peruvian patients with hepatocellular carcinomas. PLoS ONE. 2014;9:e114912.CrossRefPubMedPubMedCentral Marchio A, Bertani S, Rojas-Rojas T, Doimi F, Terris B, Deharo E, et al. A peculiar mutation spectrum emerging from young Peruvian patients with hepatocellular carcinomas. PLoS ONE. 2014;9:e114912.CrossRefPubMedPubMedCentral
31.
go back to reference Traoré F, Gormally E, Villar S, Friesen M, Groopman J, Vernet G, et al. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. BMC Infect Dis. 2015;15:180.CrossRefPubMedPubMedCentral Traoré F, Gormally E, Villar S, Friesen M, Groopman J, Vernet G, et al. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. BMC Infect Dis. 2015;15:180.CrossRefPubMedPubMedCentral
32.
go back to reference Kimbi G, Kew M, Yu M, Arakawa K, Hodkinson J. 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1185–90.CrossRefPubMed Kimbi G, Kew M, Yu M, Arakawa K, Hodkinson J. 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1185–90.CrossRefPubMed
33.
go back to reference Igetei R, Otegbayo J, Ndububa D, Lesi O, Anumudu C, Hainaut P, et al. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol. 2008;7:339–44.PubMed Igetei R, Otegbayo J, Ndububa D, Lesi O, Anumudu C, Hainaut P, et al. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. Ann Hepatol. 2008;7:339–44.PubMed
34.
go back to reference Tchana A, Moundipa P, Tchouanguep F. Aflatoxin contamination in food and body fluids in relation to malnutrition and cancer status in Cameroon. Int J Environ Res Public Health. 2010;7:178–88.CrossRefPubMedPubMedCentral Tchana A, Moundipa P, Tchouanguep F. Aflatoxin contamination in food and body fluids in relation to malnutrition and cancer status in Cameroon. Int J Environ Res Public Health. 2010;7:178–88.CrossRefPubMedPubMedCentral
35.
go back to reference Njumbe Ediage E, Diana Di Mavungu J, Song S, Sioen I, De Saeger S. Multimycotoxin analysis in urines to assess infant exposure: a case study in Cameroon. Environ Int. 2013;58:50–9.CrossRef Njumbe Ediage E, Diana Di Mavungu J, Song S, Sioen I, De Saeger S. Multimycotoxin analysis in urines to assess infant exposure: a case study in Cameroon. Environ Int. 2013;58:50–9.CrossRef
36.
go back to reference Abia W, Warth B, Sulyok M, Krska R, Tchana A, Njobeh P, et al. Bio-monitoring of mycotoxin exposure in Cameroon using a urinary multi-biomarker approach. Food Chem Toxicol. 2013;62:927–34.CrossRefPubMed Abia W, Warth B, Sulyok M, Krska R, Tchana A, Njobeh P, et al. Bio-monitoring of mycotoxin exposure in Cameroon using a urinary multi-biomarker approach. Food Chem Toxicol. 2013;62:927–34.CrossRefPubMed
37.
go back to reference Kirk G, Lesi O, Mendy M, Szymañska K, Whittle H, Goedert J, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–67.CrossRefPubMed Kirk G, Lesi O, Mendy M, Szymañska K, Whittle H, Goedert J, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–67.CrossRefPubMed
38.
go back to reference Lleonart M, Kirk G, Villar S, Lesi O, Dasgupta A, Goedert J, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomark Prev. 2005;14:2956–62.CrossRef Lleonart M, Kirk G, Villar S, Lesi O, Dasgupta A, Goedert J, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomark Prev. 2005;14:2956–62.CrossRef
39.
go back to reference El-Din H, Ghafar N, Saad N, Aziz M, Rasheed D, Hassan E. Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma. Arch Med Sci. 2010;3:348–55.CrossRef El-Din H, Ghafar N, Saad N, Aziz M, Rasheed D, Hassan E. Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma. Arch Med Sci. 2010;3:348–55.CrossRef
40.
go back to reference Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23:2471–7.CrossRefPubMed Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23:2471–7.CrossRefPubMed
41.
go back to reference Xue X, Teare M, Holen I, Zhu Y, Woll P. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009;404:100–4.CrossRefPubMed Xue X, Teare M, Holen I, Zhu Y, Woll P. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009;404:100–4.CrossRefPubMed
42.
go back to reference Lu J, Liang Z. Circulating free DNA in the era of precision oncology: pre- and post-analytical concerns. Chron Dis Transl Med. 2016;2:223–30. Lu J, Liang Z. Circulating free DNA in the era of precision oncology: pre- and post-analytical concerns. Chron Dis Transl Med. 2016;2:223–30.
43.
go back to reference Fleischhacker M, Schmidt B, Weickmann S, Fersching D, Leszinski G, Siegele B, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412:2085–8.CrossRefPubMed Fleischhacker M, Schmidt B, Weickmann S, Fersching D, Leszinski G, Siegele B, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412:2085–8.CrossRefPubMed
44.
go back to reference Poulou L, Botsa E, Thanou I, Ziakas P, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1054–63.CrossRefPubMedPubMedCentral Poulou L, Botsa E, Thanou I, Ziakas P, Thanos L. Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1054–63.CrossRefPubMedPubMedCentral
45.
go back to reference McWilliams J, Yamamoto S, Raman S, Loh C, Lee E, Liu D, et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol. 2010;21:S204–13.CrossRefPubMed McWilliams J, Yamamoto S, Raman S, Loh C, Lee E, Liu D, et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol. 2010;21:S204–13.CrossRefPubMed
Metadata
Title
Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma
Authors
Agnès Marchio
Marie Amougou Atsama
Aubin Béré
Narcisse-Patrice Komas
Dominique Noah Noah
Paul Jean Adrien Atangana
Serge-Magloire Camengo-Police
Richard Njouom
Claudine Bekondi
Pascal Pineau
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 3/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-018-0502-9

Other articles of this Issue 3/2018

Clinical and Experimental Medicine 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.